Immuron Limited Form 20-F Summary
Business context and reporting period
Immuron Limited is an Australian commercial- and clinical-stage biopharmaceutical company reporting under IFRS in Australian dollars for the fiscal year ended June 30, 2026. Its platform uses orally delivered hyper-immune bovine-colostrum antibodies targeting pathogens and toxins in the gastrointestinal tract.
- Commercial products include Travelan in Australia, the United States and Canada, and ProIBS in Australia. Protectyn was cancelled and removed from the Australian Register for Therapeutic Goods in June 2026.
- Clinical-stage assets include IMM-124E/Travelan for travelers’ diarrhea and IMM-529 for Clostridioides difficile infection.
- The ADSs trade on Nasdaq under IMRN; ordinary shares trade on the ASX under IMC. Each ADS represents 40 ordinary shares.
- Ordinary shares outstanding at June 30, 2026: 322,848,081.
Financial performance and position
| Metric | FY2026 | FY2025 | Change |
|---|---|---|---|
| Revenue | A$7.714 million | A$7.287 million | +6% |
| Gross profit | A$4.975 million | A$4.765 million | +A$0.210 million |
| Gross margin | 64.5% | 65.4% | Down 0.9 percentage points |
| Operating loss | A$3.851 million | A$5.345 million | Improved A$1.494 million |
| Net loss | A$3.680 million | A$5.216 million | Improved 29% |
| Basic and diluted loss per share | 1.24 Australian cents | 2.26 Australian cents | Improved |
| Cash used in operating activities | A$3.260 million | A$6.137 million | Use decreased 47% |
| Cash and cash equivalents | A$9.018 million | A$2.831 million | +A$6.187 million |
| Total liabilities | A$1.987 million | A$2.061 million | Down A$0.074 million |
| Accumulated losses | A$84.970 million | A$82.443 million | Increased |
Revenue was generated entirely from hyper-immune products. Travelan revenue was A$5.673 million in Australia, A$1.768 million in the United States and A$0.166 million in Canada. ProIBS contributed A$0.085 million in Australia.
Other income was A$1.170 million, including an Australian R&D tax incentive refund of A$0.782 million and an HJF R&D grant of A$0.340 million. No MTEC grant income was recognized in FY2026.
Inventory increased to A$2.274 million from A$1.773 million. Total assets were A$13.152 million and net assets were A$11.165 million. The company reported no borrowings or credit facilities and no material contingent liabilities or off-balance-sheet arrangements.
Material changes versus the prior comparable period
- Revenue increased 6%, led by Travelan growth in Australia and the United States. Australian Travelan revenue rose more than 9%, while U.S. revenue increased 7%. Canadian revenue declined.
- Gross profit increased, but gross margin declined because cost of goods sold grew faster than revenue.
- Research and development expense declined 46% to A$1.933 million, reflecting reduced activity after the December 2025 failure of the P2TD study’s primary endpoint to achieve statistical significance.
- General and administrative expense decreased 4%; selling and marketing expense was broadly flat.
- Operating cash outflow improved substantially, while financing provided A$6.475 million, principally from ATM equity issuance net of issuance costs.
- The company issued substantial equity through its ATM facility during FY2026. Issued capital increased to A$95.656 million and shares outstanding increased from 233.959 million to 322.848 million, before the cancellation of 3.806 million unmarketable-parcel shares.
- The investment in Ateria Health remained fully impaired at nil.
- Management identified a material weakness in inventory accounting and concluded that internal control over financial reporting and disclosure controls were not effective at June 30, 2026.
Guidance, outlook, commentary and risks
- Management expects continued losses and states that additional capital may be required to fund clinical development, regulatory activities, manufacturing scale-up and operating expenses.
- Management believes current cash and cash equivalents are sufficient to fund capital requirements for at least 12 months from issuance of the financial statements and prepared the accounts on a going-concern basis. This outlook depends on sales, grants, financing, partnerships and clinical-development spending.
- Immuron plans to pursue an FDA end-of-Phase 2 discussion regarding a Phase 3 strategy for Travelan using the established three-times-daily dosing regimen. The P2TD field study did not support the proposed twice-daily regimen; management cited delayed dosing, missed doses, non-compliance and dosing with meals as possible contributors.
- The FDA accepted the IMM-529 IND. A Phase 2 study of up to 60 subjects with standard of care is planned in Australia, while the company seeks development partners.
- On September 4, 2026, after the reporting date, Immuron announced an exclusive U.S. ProIBS distribution agreement with Calmino Group AB.
- Key risks include recurring operating losses, dependence on future financing, clinical and regulatory uncertainty, limited prescription-product experience, reliance on third-party manufacturers and clinical research organizations, single-source manufacturing for key assets, competition, intellectual-property challenges, foreign-exchange exposure and potential changes to Australia’s R&D tax incentive.
- Proposed Australian R&D tax incentive changes could make Immuron ineligible for future refunds because it has operated for more than 10 years. The filing does not state that these proposed changes have been enacted.
- The company has never paid dividends and does not anticipate paying dividends in the foreseeable future.
Most important facts for investors to verify
- Verify the company’s cash runway, planned clinical expenditures and expected timing and terms of future equity financing.
- Review the inventory-related material weakness, remediation progress and any effect on inventory valuation or cost of goods sold.
- Confirm the regulatory and clinical path for Travelan, including the FDA end-of-Phase 2 meeting and any Phase 3 requirements.
- Track initiation, enrollment, safety and efficacy results for the IMM-529 Phase 2 study and the status of potential partners.
- Assess whether Travelan and ProIBS sales growth can offset continuing R&D, marketing and corporate costs.
- Evaluate dilution from the ATM financing, outstanding options and performance rights; 11.767 million options and performance rights were outstanding at June 30, 2026.
- Confirm the final implementation and effect of proposed Australian R&D tax incentive changes.
- Review the terms and commercial impact of the post-period U.S. ProIBS distribution agreement.